Identification
Instrument name
MITHRA
Symbol
MITRA
ISIN code
BE0974283153
Exchange / Market
Euronext
Trading location
Brussels
Products family
Stocks
Capitalization compartment
Compartment B
ICB
Pharmaceuticals
Website address
http://www.mithra.be
Operation
IPO date
Issue type
Initial Public offering
Catégorie
IPO
Price range
EUR 10.50 - EUR 12.50

Company profile

Mithra Pharmaceuticals specializes in the development of women's health care products that are dedicated to the fields of contraception, fertility, and menopause. The three lead development candidates Estelle® (a fifth generation oral contraceptive), PeriNesta™ (first full oral treatment against perimenopause) and Donesta® (a next generation hormone therapy) are built on Mithra's unique natural estrogen platform, E4 (Estetrol). The group also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO.

Source: Cofisem - Last Update: 19 Jul 2019
Key Executives
Chief Executive Officer Francois Fornieri
Company Secretary Michael Dillen
Chief Financial Officer Christophe Maréchal
Investor Relations Alexandra Deschner
Source: Cofisem - Last Update: 19 Jul 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 65,465 46,252 22,468 20,435 19,038
Income from ordinary activities 65,465 46,252 22,468 20,435 19,038
Operating income 35,457 -21,081 -35,976 -14,267 -2,928
Cost (net) of financial indebtedness -3,460 -1,702 -53 -315 -206
Equity-accounted companies' contribution to results -32 -2,758 -94
Net profit from discontinued activities
Net income -12,363 -35,006 -35,087 -9,821 -2,955
Net income (Group share) -12,363 -35,006 -35,087 -9,821 -2,955
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 19 Jul 2019
Shareholder information
Free float 33.37 %
Francois Fornieri 28.17 %
Marc Coucke 16.46 %
Meusinvest 14.36 %
Bart Versluys 4.51 %
Ogesip Invest 3.13 %
Source: Cofisem - Last Update: 17 Jun 2019